News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Active Biotech AB (BTPC) Receives Tasquinimod Milestone Payment From Ipsen (IPN.PA) for 10TASQ10 Study



10/9/2013 11:09:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LUND, Sweden & PARIS--(BUSINESS WIRE)--Regulatory News: Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN) today announced that Active Biotech, under the terms of the co-development and commercialization agreement on the novel candidate drug tasquinimod, has received a milestone payment of 12 million euros from Ipsen.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES